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fibrinogen in a prospective analysis of
the ECLIPSE cohort
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Abstract
Background: Identifying subjects with chronic obstructive pulmonary disease (COPD) at high risk of
exacerbation and mortality is key to aid individual management of COPD. The only FDA approved blood-
based drug development biomarker for patients at high risk of mortality, is plasma fibrinogen. In this study,
we benchmarked two biomarkers of basement membrane remodeling, a characteristic of COPD, against
plasma fibrinogen alone and as a combination. The biomarkers of basement membrane remodeling are two
neoepitopes from of the alpha 3 chain of type IV collagen (COL4A3).
Materials and methods: COL4A3 degradation was assessed by the biomarkers C4Ma3 and tumstatin (TUM) in year 1
plasma samples in 984 COPD subjects, 95 non-smoking controls and 95 smoking controls from the Evaluation of COPD
Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) cohort. They were measured by competitive ELISA
using monoclonal antibodies recognizing two specific MMP-generated cleavage site within COL4A3. The level of
fibrinogen was previously assessed in year 1 plasma.
Results: In COPD subjects, plasma C4Ma3 levels were significantly correlated with plasma fibrinogen levels (0.389
(P < 0.0001)). Cox proportional-hazards regression adjusted for relevant confounders showed that high levels of
plasma C4Ma3, but not TUM, were related to a higher risk of mortality (hazard ratio 5.12 (95% CI 2.28–11.50),
P < 0.0001). High levels of plasma fibrinogen were not associated with all-cause mortality in this subpopulation,
contradictory to published results. Whereas plasma C4Ma3 multiplied by fibrinogen showed to be related to a
higher risk of mortality (hazard ratio 5.74 (95% CI 2.65–12.41), P < 0.0001). Plasma C4Ma3 levels were related to
the number of hospitalizations due to COPD exacerbations in the year before study start (P = 0.0375). Fibrinogen
levels were related to hospitalized exacerbations prior to study start (P = 0.0058) and were also related to future
exacerbations (P < 0.0001).
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Conclusion: We compared herein fibrinogen, C4Ma3 and TUM as biomarkers for COPD prognosis.
Fibrinogen was related to future exacerbation, whereas C4Ma3 and the combination of C4Ma3 with
fibrinogen were superior to fibrinogen alone in predicting mortality. This pilot study suggests that the
assessment of plasma C4Ma3 could be important for identifying COPD patients with a poor prognosis.
Trial registration: NCT00292552, GSK Study No. SCO104960.
Keywords: COPD, Biomarkers, Basement membrane, Collagen type IV, ECLIPSE
Background
Chronic obstructive pulmonary disease (COPD) is the third
leading cause of death worldwide [1]. It is characterized by
progressive airflow limitation related to chronic inflamma-
tion, lung tissue destruction and small airway fibrosis. Iden-
tifying patients at risk of progression as defined by a rapid
decline in forced expiratory volume in one second (FEV1),
an increased rate of exacerbations or mortality is challen-
ging but crucial for precision medicine. Plasma fibrinogen
was the first blood-based biomarker of COPD to be quali-
fied approved by the U.S. Food and Drug Administration
(FDA) in 2015 for the enrichment of subjects with COPD
at higher risk of progression in clinical trials [2, 3]. The ap-
proval was based on data from the ECLIPSE cohort, show-
ing its value as a prognostic biomarker to identify COPD
subjects at risk of exacerbations or all-cause mortality.
One of the main structural characteristics of COPD is
changes to the lung tissue due to altered extracellular
matrix (ECM) content and remodeling of the ECM. In the
distal airways and alveoli, the ECM is mainly represented
by the basement membrane (BM) with only a thin layer of
or no interstitial matrix. The ECM layer is thin, thus ensur-
ing easy transport of gases between the air and the blood
[4–6], and the alveoli contain a specialized BM that is opti-
mal for this gas transport. There are six distinct type IV col-
lagen α-chains, namely α1(IV) through α6(IV), which are
selectively expressed in different membranes at various
stages of development and in specific tissues [5, 7]. The
α1α1α2(IV) isoform is ubiquitous, but the alveolar BM, as
well as the glomerular BM, also contains the specialized
α3α4α5(IV) isoform that facilitates gas exchange [8, 9]. The
function of type IV collagen in both lungs and kid-
neys indicates that this specialized isoform is import-
ant for the diffusion across the BM barrier in these
two organs. The α3α4α5(IV) isoform has been shown
to contain a high number of disulfide cross-links and
consequently to be more resistant to proteolytic deg-
radation than α1α1α2(IV). Thus, the α3α4α5(IV) may
be better suited for the more vulnerable position in the al-
veolar BM [10]. This makes α3α4α5(IV) a very specific
collagen type IV isoform of the lungs.
Alterations in the BM influence the processes of lung in-
jury and repair, implying an important role for type IV
collagen in pulmonary diseases. For example, the disruption
of the alveolar BM as a result of matrix metalloproteinase
(MMP) activity is a consistent finding in idiopathic pul-
monary fibrosis (IPF) [11], that may contribute to aberrant
lung remodeling by hindering re-epithelialization and en-
hancing fibroblast invasion mediated by increasing perme-
ability [12]. Thus, the remodeling of type IV collagen may
also be crucial in the pathogenesis of COPD.
Fibrinogen is a coagulation factor that is essential for
the blood clotting process in tissues following injury.
Plasma levels of fibrinogen have been shown to predict
acute exacerbations of COPD as well as all-cause mor-
tality [2, 3]. However, plasma fibrinogen levels may rise
in response to extrapulmonary injury and systemic in-
flammation in COPD which makes it less specific for
disease activity specifically in the lung.
In this study, we investigated BM remodeling as a risk
biomarker for COPD disease progression as defined by al-
terations in lung tissue structure. More specifically, we
evaluated the alveolar BM remodeling by measuring the
serological biomarker (C4Ma3) reflecting MMP-mediated
degradation of the type IV collagen alpha 3 chain and
tumstatin (TUM) the C-terminal non-collagenous (NC1)
domain of the type IV collagen alpha 3 chain. BM remod-
eling may be more specific for the changes that occur in
the lung of COPD patients as compared to plasma fibrino-
gen and therefore potentially a better prognostic bio-
marker alone or incremental to the prognostic value of
fibrinogen. To investigate this, we benchmarked the
performance of BM remodeling against plasma fibrino-
gen and a combination of plasma C4Ma3 and fibrino-
gen in relation to acute exacerbations and mortality
outcome in subjects with COPD. We conducted a ret-
roprospective analysis of the plasma C4Ma3, TUM and
fibrinogen in a subset of the three-year Evaluation of




The study design of ECLIPSE (clinicaltrials.gov identifier
NCT00292552; GSK study code SCO104960) has been
described in detail previously [13, 14]. Briefly, ECLIPSE
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is an observational, longitudinal study which evaluated
participants at baseline and at months three, six, and
subsequently every six months for three years. For the
current analyses, we used clinical and biomarker data
obtained at year one and year three. Death was recorded
up to day 1060 in year three of the study. Cause of death
was not available for the present analyses. ECLIPSE
complies with the Declaration of Helsinki and Good
Clinical Practice Guidelines and has been approved by
the ethics committees of the participating centers. All
participants provided written informed consent before
the performance of any study-related assessments.
Population
The full ECLIPSE study included 2164 participants di-
agnosed with COPD based on a post-bronchodilator
FEV1 < 80% of the reference value, FEV1/forced vital
capacity (FVC) ≤ 0.7, and a smoking history of ≥10
pack-years [13, 14]. The cohort was recruited from
the outpatient clinics of the participating centers. The
current study was performed on a subpopulation of
1000 COPD subjects of the ECLIPSE cohort com-
posed of 500 subjects progressing the most and 500
subjects progressing the least as defined by FEV1 de-
cline over the three-year study period. Individuals
with available plasma C4Ma3 data were included in
the analyses, giving a total of 984 COPD participants
(Fig. 1a). Additionally, plasma C4Ma3 data for smok-
ing (n = 95) and never-smoking (n = 95) controls age
gender and body mass index (BMI) matched to 95 of
the COPD subjects were included in the analyses
(Fig. 1).
Measurements of serological biomarkers
Plasma (heparin anticoagulant) samples were collected
from participants in the fasting state at year 1 by
venipuncture into vacutainer tubes followed by centrifuga-
tion at 2000 g for 10–15min. Plasma was stored at -80 °C
until analyzed. Plasma C4Ma3 and TUM levels were mea-
sured by validated competitive ELISAs utilizing monoclo-
nal antibodies targeting a specific neo-epitope of type IV
collagen generated by MMP cleavage of the alpha 3 chain
(Nordic Bioscience, Herlev, Denmark) [15, 16]. Measure-
ments were performed in a blinded manner according to
the manufacturer’s instructions. Analytes detected by this
assay are stable in plasma samples that have undergone at
least four freeze/thaw cycles [15]. Prior to this study,
plasma fibrinogen levels were measured in year one
plasma (dry ethylenediaminetetraacetic acid anticoagu-
lant) samples as described previously [17]. As measure-
ments were performed in plasma and not in serum, in
order to be able to compare fibrinogen results to the typ-
ically used liquid sodium citrate anti-coagulant, the pub-
lished cut-off level, plasma fibrinogen levels were
corrected by − 13.6%, as described in the statistical ana-
lysis plan from the COPD Biomarkers Qualification Con-
sortium for their FDA application (Supplements for [18]).
Statistical analysis
Basic demographics were compared using Mann-Whitney
U test, Kruskal-Wallis test, or chi-squared test as appro-
priate. Plasma C4Ma3, TUM and fibrinogen levels were
compared between groups or with clinical parameters
using Spearman’s rank correlation, Mann-Whitney U test
or Kruskal-Wallis test as appropriate.
Fig. 1 Study recruitment and participant flow. a COPD participants. b controls
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The association of plasma C4Ma3 and plasma fibrino-
gen with future and prior acute exacerbations was inves-
tigated by logistic regression.
Cox proportional hazards analyses were used to assess
the prognostic value of plasma C4Ma3, TUM and fi-
brinogen levels for all-cause mortality for one standard
deviation (SD) increase in the biomarker. Plasma C4Ma3
data were dichotomized based on receiver operating
curve (ROC) analyses. The ROC curve had an area under
the curve (AUC) of 0.68 (95% CI 0.65–0.71), P = 0.0005,
and gave a cut-off of 5.5 ng/mL for the identification of
subjects who died with a sensitivity of 40.0 and specificity
of 90.8. Plasma fibrinogen data were dichotomized based
on the published cut-off level of 350mg/dL. A cut-off
value for plasma C4Ma3 multiplied by plasma fibrino-
gen (C4Ma3*Fibrinogen) was defined by a ROC ana-
lysis for identification of COPD subjects at risk of
mortality. The ROC curve had an AUC of 0.68 (95%
CI 0.58–0.80, P = 0.0004) and gave a cut-off of 2037
for the identification of subjects who died with a sen-
sitivity of 53.3 and specificity of 83.9. Mortality risk
for groups below and above the cut-off was compared
using Cox proportional hazards analysis with or with-
out relevant confounders as determined by univariate
Cox proportional hazards analysis. Kaplan-Meier sur-
vival curves compared the mortality risk for patients
belonging to the high vs. low biomarker groups. All
tests performed (MedCalc Statistical Software version
16.8.4, MedCalc Software bvba, Ostend, Belgium)
were two-sided at the 0.05 level of significance, and
all P values are nominal as no adjustments were
made for multiple comparisons.
Results
C4Ma3 is increased in COPD patients
Levels of plasma C4Ma3 were significantly different
between COPD and matched control participants
(P = 0.0047). Group analysis showed that plasma C4Ma3
levels were significantly elevated in COPD subjects (me-
dian 38 pack years) as compared to never-smoking, but
not smoking controls (median 30 pack-years) (Table 1/
Fig. 2). Plasma fibrinogen level was significantly increased
in COPD subjects compared to smoking controls and
never-smoking controls (Table 1/Fig. 2). Whereas, TUM
did not show any difference between the three groups
(Fig. 2). In COPD subjects, plasma C4Ma3 levels were
significantly correlated with plasma fibrinogen levels
(Spearman’ correlation coefficient 0.389 (P < 0.0001).
Basic demographics
Basic demographics for the full COPD population are
shown in Table 2. Mean age was 63.1 (7.2) years, BMI
was 26.8 (5.9), and 357 (36%) were female. Mean
pack-years were 47.4 (26.0) and 363 (37%) were current
smokers. Post-bronchodilator FEV1 was a mean of 50.6%
(15.2) of predicted value, 558 (57%) had significant em-
physema, 439 (45%) reported one or more exacerbation
in the year prior to study start, and 30 (3%) died from
year one to the end of the study period (year three).
C4Ma3 may be superior to fibrinogen in predicting
mortality
COPD subjects which were registered as dead as com-
pared to alive at the end of the study period had signifi-
cantly higher levels of plasma C4Ma3, TUM and
fibrinogen (P = 0.0008, P = 0.0467 and P = 0.0006, re-
spectively) (Table 2/Fig. 3). Univariate Cox proportional
hazard regression showed age, smoking status, 6-min
walk distance (6MWD), modified Medical Research
Council (mMRC) dyspnea score, and prior hospitaliza-
tions due to acute exacerbations to influence mortality
risk (Table 3). Cox regression analysis adjusted for age,
smoking status, prior hospitalizations due to exacerba-
tions, mMRC and 6MWD showed that plasma C4Ma3
Table 1 Demographic characteristics of COPD subjects and controls
Parameter Smoking controls Never-smoking controls COPD P value
n 95 95 95
Age, mean (SD) 59.4 (7.2) 58.8 (7.6) 60.0 (6.4) 0.663 ¥
Female gender, n (%) 47 (49%) 47 (49%) 47 (49%) 1.000 £
BMI, mean (SD) 27.4 (4.3) 28.4 (4.5) 27.4 (5.5) 0.239 ¥
Pack-years, median (IQR) 30 (18–40) 0 (0–0) 38 (30–48) < 0.0001 ¥
Current smokers, n (%) 47 (49%) 0 (0%) 47 (49%) < 0.0001 £
Cardiovascular history, n (%) 26 (27%) 16 (17%) 21 (22%) 0.217 £
Post bronchodilator FEV1 (% predicted), mean (SD) 110.3 (13.6) 114.0 (13.7) 53.3 (15.6) < 0.0001 ¥
C4Ma3 (ng/mL), median (IQR) 3.04 (2.44–3.85) 2.76 (2.20–3.35) 3.12 (2.46–4.22) 0.0047 ¥
TUM (ng/mL), median (IQR) 0.71 (0.64–0.78) 0.63 (0.60–0.73) 0.73 (0.63–0.80) 0.263 ¥
Fibrinogen (mg/dL), median (IQR) 343.4 (311.0–383.6) 326.6 (287.7–375.8) 356.4 (318.8–421.2) 0.0009 ¥
¥ Kruskal-Wallis; £ Chi-squared test
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was an independent predictor of mortality with a
hazard ratio of 1.57 (95% CI 1.29–1.92) per SD increase
(P < 0.0001), whereas TUM showed not to be an inde-
pendent predictor of mortality. Plasma fibrinogen
showed similar results as C4Ma3 with a hazard ratio of
1.62 (95% CI 1.31–1.99) per SD increase (P < 0.0001)
(Table 3). Plasma C4Ma3 values were dichotomized
into a high and a low group based on a ROC curve,
which was analyzed by Kaplan-Meier survival curve
(Fig. 4a). For comparison, plasma fibrinogen was ana-
lyzed using the published cut-off value of 350 mg/dL
(Fig. 4b) [18]. Cox proportional hazards regression was
used for assessing the risk of mortality in high vs low
group in a crude and adjusted analysis. The hazard ra-
tio for the high plasma C4Ma3 group was 4.68 (95% CI
1.40–15.71, P < 0.0001). Here, 10.3% of subjects in the
high group died while only 2.3% of the subjects died in
the low C4Ma3 group. The hazard ratio for the high
plasma fibrinogen group was 3.30 (95% CI 1.55–7.03, P
= 0.0186). In the adjusted analysis high C4Ma3 level,
age, and former smoking were included in the model
while prior hospitalized acute exacerbations, mMRC
dyspnea score and 6MWD were not significant. This
model provided a hazard ratio for being in the high
plasma C4Ma3 group of 5.12 (95% CI 2.28–11.50, P =
0.0001). A similar model with high plasma fibrinogen
level showed fibrinogen to be non-significant and in-
stead, the model included age, former smoking and
mMRC dyspnea score. In addition, adding both high
C4Ma3 and high Fibrinogen to a model only included
age, smoking and plasma C4Ma3 providing a hazard
ratio for being high in plasma C4Ma3 of 3.75 (95% CI
1.60–8.80, P = 0.0024). High levels of fibrinogen
showed to be non-significant (Table 4).
Combining C4Ma3 and fibrinogen improves prediction of
mortality
To investigate if the added effects of plasma C4Ma3
and fibrinogen could provide additional predictive
value, we forced the two biomarkers into a model in
addition to age and smoking status. Cox proportional
hazards regression was used to assess the risk of mor-
tality in high vs low groups in an adjusted analysis de-
fined by a ROC curve. This model provided a hazard
ratio for being in the high plasma C4Ma3*Fibrinogen
group of 5.74 (95% CI 2.65–12.41), P < 0.0001, which
was higher than both plasma C4Ma3 and plasma fi-
brinogen individually. Age and former smoking were
included in the model while prior hospitalized acute ex-
acerbations, mMRC dyspnea score and 6MWD were
not. (Table 5).
C4Ma3 is related to hospitalized exacerbations
Plasma C4Ma3 levels were related to the number of hos-
pitalizations due to COPD exacerbations in the year
prior to study start (Kruskal-Wallis P = 0.0375) (Fig. 5a).
Levels were not able to predict any future self-reported
exacerbations (data not shown). Plasma fibrinogen levels
were related to hospitalized exacerbations prior to study
start (Kruskal-Wallis P = 0.0058) (Fig. 5b) as well as be-
ing related to future exacerbations in the year following
biomarker measurement (Kruskal-Wallis P ≥ 0.0001)
(data not shown). To find out if high plasma C4Ma3 and
high plasma fibrinogen alone were able to predict exac-
erbations in the following year, a logistic regression was
performed. BMI, airflow Obstruction, Dyspnea and Exer-
cise capacity index (BODE) and mMRC dyspnea score
were included in the model while age, former smoking,
and 6MWD were not significant. Only the BODE index
was able to predict exacerbations in the following year.
This was also the case when including high C4Ma3*Fi-
brinogen in the model.
Discussion
Identifying patients at highest risk of progression or the
highest disease activity and determining responders ver-
sus non-responders to a disease-modifying drug in ex-
pensive clinical trials would be valuable to COPD
Fig. 2 Plasma C4Ma3 (a), TUM (b) and fibrinogen (c) levels in matched never-smoking controls (NSC), smoking controls (SC), and COPD subjects. Each
group n = 95. Data are shown as Tukey box-and-whiskers plot with a line indicating median, the box indicating the 25th and 75th percentiles (the
interquartile range, IQR), and whiskers indicating 1.5 times the IQR. Data points outside this limit are shown by individual data points. Data were
analyzed by Kruskal-Wallis test using Dunn’s multiple comparison. Asterisks indicate statistical significance: **p < 0.01, and ****p < 0.0001
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subjects. Biomarkers of disease activity are not only
needed to accelerate drug development but also to
understand the heterogeneity of COPD, which can make
it difficult to diagnose and choose the right treatment
for each patient. We benchmarked the only FDA ap-
proved blood-based biomarker of COPD, plasma fibrino-
gen, with biomarkers reflecting BM remodeling by
measuring the degradation of COL4A3, by plasma
C4Ma3 and TUM. We found that C4Ma3 was highly as-
sociated with all-cause mortality and showed to be su-
perior to fibrinogen in predicting mortality since COPD
subjects being high in C4Ma3 had a poorer prognosis
than those with low C4Ma3 levels. More interestingly,
combining C4Ma3 and fibrinogen was able to improve the
prediction of mortality compared to C4Ma3 and fibrinogen
alone. In contrast, plasma fibrinogen was related to future
self-reported exacerbations whereas C4Ma3 was only re-
lated to prior hospitalized exacerbations. The combination
of fibrinogen and C4Ma3 was not able to predict future ex-
acerbations either. Furthermore, the data indicated the im-
portance of COL4A3 fragments, since the results for
C4Ma3 and TUM were different.
The rate of BM remodeling is proposed to be increased
during periods of high disease activity and faster disease
progression [19]. Furthermore, it has been shown by
Schumann et al. that plasma C4Ma3 levels were increased
Table 2 Basic Demographics
Parameter COPD Survivors Deceased P value (survivors vs. deceased)
n 984 954 30
Age, mean (SD) 63.1 (7.2) 62.9 (7.2) 68.2 (6.3) < 0.0001 ¥
Female gender, n (%) 357 (36%) 346 (36%) 11 (37%) 0.964 £
BMI, mean (SD) 26.8 (5.9) 26.8 (5.8) 27.3 (7.8) 0.777 ¥
Pack-years, mean (SD) 47.4 (26.0) 47.1 (25.3) 55.9 (42.5) 0.934 ¥
Current smokers, n (%) 363 (37%) 360 (38%) 3 (10%) 0.002 £
Cardiovascular history, n (%) 310 (32%) 298 (31%) 12 (40%) 0.309 £
Post bronchodilator FEV1 (% predicted), mean (SD) 50.6 (15.2) 50.6 (15.3) 48.5 (13.0) 0.384 ¥
GOLD stage, n (%) 0.695 £
2 487 (49%) 473 (50%) 14 (47%)
3 397 (40%) 383 (40%) 14 (47%)
4 100 (10%) 98 (10%) 2 (7%)
GOLD stage, n (%) 0.231 £
A 250 (25%) 244 (26%) 6 (20%)
B 128 (13%) 121 (13%) 7 (23%)
C 226 (23%) 222 (23%) 4 (13%)
D 339 (34%) 329 (34%) 10 (33%)
mMRC score, median (IQR) 1 (1–2) 1 (1–2) 2 (1–3) 0.022 ¥
SGRQ-C total score, median (IQR) 47.2 (33.2–60.6) 47.2 (33.2–60.2) 53.3 (33.0–66.0) 0.294 ¥
6MWD (meters), mean (SD) 385.4 (119.0) 387.0 (119.1) 335.3 (105.0) 0.013 ¥
FV950 baseline, mean (SD) 16.3 (11.3) 16.2 (11.3) 17.4 (10.5) 0.425 ¥
Emphysema (%LAA≥ 10%), n (%) 558 (57%) 538 (56%) 20 (67%) 0.264 £
Number of hospitalized exacerbations in year
prior to study, mean (SD)
0.16 (0.53) 0.16 (0.52) 0.37 (0.85) 0.036 ¥
BODE index, median (IQR) 3.0 (1.0–4.0) 3.0 (1.0–4.0) 3.5 (2–5) 0.065 ¥
Dead by end of study, n (%) 30 (3%) 0 (0%) 30 (100%) < 0.0001 £
Survival time (days), mean (SD) 1056 (28) 1060 (0) 922 (84) < 0.0001 ¥
C4Ma3 (ng/mL), median (IQR) 3.28 (2.55–4.33) 3.25 (2.54–4.30) 4.02 (3.16–6.05) 0.0008 ¥
TUM (ng/mL), median (IQR) 0.71 (0.69–0.74) 0.71 (0.69–0.73) 0.79 (0.71–1.17) 0.0467 ¥
Fibrinogen (mg/dL), median (IQR) 378.4 (334.4–434.1) 377. 6 (333.5–432.0) 445.4 (359.4–527.0) 0.0006 ¥
¥ Mann-Whitney; £ Chi-squared test. Data are shown as mean ± SD, median (25th, 75th) or number (%). BMI body mass index, FEV1 post-bronchodilator forced
expiratory volume in 1 s, GOLD global initiative for chronic obstructive lung disease, mMRC modified Medical Research Council dyspnea score, SGRQ St. George’s
respiratory questionnaire, 6MWD 6-min walk distance, %LAA percent low attenuation area at −950 Hounsfield units, BODE BMI, airflow obstruction, dyspnea and
exercise capacity index, FACIT functional assessment of chronic illness therapy fatigue score
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in COPD subjects from the stable state to the exacerba-
tion and in a hospitalized exacerbation compared to a
moderate exacerbation [20]. We showed in this study that
plasma C4Ma3 levels were related to previous hospitalized
acute exacerbations, which may indicate that plasma
C4Ma3 may represent continuous disease activity that re-
sults from previous severe events. Plasma fibrinogen was
related to hospitalized exacerbations but also self-reported
exacerbations, indicating that fibrinogen is more related
to exacerbations than C4Ma3. Furthermore, fibrinogen
was related to future exacerbations, which was not the
case for C4Ma3.
Disease activity is not necessarily correlated with dis-
ease severity, patients with severe airflow limitation may
not decrease further in FEV1 and thereby not be high in
disease activity [21, 22]. Since C4Ma3 was proposed as a
disease activity marker no correlation was observed with
levels of airflow limitation as defined by FEV1.
Fibrinogen showed similar results. Instead, this study
showed that plasma C4Ma3 was an independent pre-
dictor of mortality outcome. Using a cut-off level of 5.5
ng/mL for C4Ma3, dividing the COPD subjects into high
versus low biomarker levels, showed that COPD subjects
with high biomarker levels had a poorer prognosis than
those with low biomarker levels. Fibrinogen was not able
to predict mortality when using the already published
cut-off value of 350 mg/dL in a larger cohort [18] and
this may reflect a weaker predictive value.
Fibrinogen is an acute phase soluble plasma glycopro-
tein, synthesized primarily in the liver and proteolytically
cleaved by thrombin into fibrin during blood coagula-
tion, making it a potential biomarker for systemic
chronic wound healing [23]. COL4A3 is abundantly
expressed in the normal alveolar and glomerular BM,
but not in the rest of the body, making C4Ma3 and
TUM more specific to the lung. Moreover, COL4A3 has
Fig. 3 Plasma C4Ma3 (a), plasma TUM (b) and plasma fibrinogen (c) levels in survivors (n = 954) versus deceased (n = 30) COPD subjects. Data are
shown as Tukey box-and-whiskers plot with a line indicating median, the box indicating the 25th and 75th percentiles (the interquartile range,
IQR), and whiskers indicating 1.5 times the IQR. Data points outside this limit are shown by individual points. Asterisks indicate statistical
significance: ***p < 0.001
Table 3 Cox regression in relation to mortality risk
Parameter Hazard ratio (95% CI) P value
Age 1.14 (1.0654–1.2201) 0.0001
BMI 1.01 (0.9548–1.0752) 0.6640
BODE 1.17 (0.9828–1.3958) 0.0774
Current smoking 0.17 (0.0564–0.6132) 0.0057
6MWD 0.99 (0.99–1.00) 0.0205
mMRC dyspnea score 1.55 (1.11–2.17) 0.0106
Prior AECOPD 1.00 (0.74–1.37) 0.98
Prior hospitalizations due to AECOPD 1.52 (1.02–2.26) 0.0375
C4Ma3 per SD 1.65 (1.33–2.03) < 0.0001
C4Ma3 per SD (adjusted for confounders) 1.57 (1.29–1.92) < 0.0001
TUM per SD 1.307 (1.08–1.58) 0.0064
Fibrinogen per SD 1.58 (1.28–1.94) < 0.0001
Fibrinogen per SD (adjusted for confounders) 1.62 (1.31–1.99) < 0.0001
Cox regression in relation to mortality risk. BMI body mass index, BODE BMI, airflow obstruction, dyspnea and exercise capacity index, 6MWD 6-min walk distance,
mMRC modified Medical Research Council score, AECOPD acute exacerbations of chronic pulmonary disease. Confounders included age, current smoking status,
6MWD, mMRC score and prior hospitalizations due to AECOPD
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been shown to inhibit the activation of neutrophils and
endothelial cell proliferation, and to induce cell apop-
tosis by its NC1 domain, tumstatin [24–26]. Tumstatin
has been shown to have antiangiogenic effects by block-
ing the interaction between vascular endothelial growth
factor (VEGF) and αVβ3 integrin leading to apoptosis of
proliferating endothelial cells [27, 28]. This suggests that
COL4A3 may be involved in the development of COPD
by modulating the inflammatory response or alveolar
cell apoptosis [24]. This supports the idea that measur-
ing COL4A3 degradation is interesting for COPD not
only by predicting mortality and hospitalized exacerba-
tions but also with a potential role in understanding
pathways associated with the pathogenesis of COPD.
Notably, the data highlight the importance of knowing
the specific fragment that are measured, since the results
for C4Ma3 and TUM were different.
Fibrinogen and the biomarker C4Ma3 reflect two
different aspects of COPD and by combining the two
markers COPD patients with chronic wound healing
and remodeling in the basement membrane of the
lungs may be identified. We, therefore, speculated
that combining the two markers would be a superior
prognostic predictor relative to fibrinogen and C4Ma3
alone. C4Ma3*Fibrinogen improved the prediction of
mortality but did not add to the predictive value for
self-reported exacerbations.
A key limitation of our study is that data were gener-
ated for a subpopulation of the full ECLIPSE study com-
prising the study participants that progress the least and
the most in terms of FEV1 decline over 3 years which
may explain the low number of mortality events and re-
duced statistical power. Despite this, we found signifi-
cant associations with mortality for C4Ma3 which seems
promising and worthy of replication in larger studies.
Additionally, baseline samples were not available, short-
ening the true follow-up time to two years. However, as
this was an observational study it should not interfere
with the interpretation of the results. Here, we compared
a cutoff for C4Ma3 found by ROC curve in the current
study with a published cutoff for fibrinogen. To deter-
mine if the associations are applicable to the general
COPD population and to confirm if C4Ma3 is superior
to fibrinogen in predicting mortality, the results should,
therefore, be confirmed in an independent cohort.
In conclusion, we were able to compare fibrinogen,
C4Ma3 and TUM as biomarkers of disease activity in
COPD, alone and in combination. We showed that high
levels of plasma C4Ma3 were associated with poorer
prognosis and that plasma C4Ma3 levels were related to
Fig. 4 Kaplan-Meier survival curve analysis using the cut-off 5.5 ng/mL plasma C4Ma3 (a) and the cut-off of 350 mg/dL plasma fibrinogen (b)
Table 4 Cox regression using cut-off levels for C4Ma3 and
fibrinogen
Parameter Hazard ratio (95% CI) P value
Model 1 (high C4Ma3)
High C4Ma3 5.12 (2.28–11.50) 0.0001
Age 1.11 (1.03–1.19) 0.0051
Former smoking 5.54 (1.30–23.60) 0.0206
Model 2 (high Fibrinogen)
Age 1.10 (1.03–1.19) 0.0079
Former smoking 4.82 (1.12–20.65) 0.0342
mMRC dyspnea score 1.45 (1.03–2.04) 0.0334
Model 3 (high C4Ma3 and high Fibrinogen)
High C4Ma3 3.75 (1.60–8.80) 0.0024
Age 1.09 (1.02–1.17) 0.0145
Former smoking 5.03 (1.17–21.62) 0.0301
Cox proportional hazards regression, enter method. Parameters tested for
inclusion in all the models: High biomarker level; Age; smoking status; prior
hospitalized acute exacerbations; mMRC modified Medical Research Council
dyspnea score and 6MWD 6-min walk distance
Table 5 Cox regression combining C4Ma3 and fibrinogen
Parameter Hazard ratio (95% CI) P value
Model 4 (High C4Ma3*Fibrinogen)
High C4Ma3*Fibrinogen 5.74 (2.65–12.41) < 0.0001
Age 1.11 (1.03–1.19) 0.0072
Former smoker 5.37 (1.26–22.86) 0.0231
Cox proportional hazards regression, enter method. Parameters tested for
inclusion in all the models: High biomarker level; Age; smoking status; prior
hospitalized acute exacerbations; mMRC modified Medical Research Council
score and 6MWD 6-min walk distance
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hospitalization due to exacerbation prior to study start.
Plasma fibrinogen was not related to mortality using the
published cut-off value of 350 mg/dL but showed to be
associated with both hospitalized and self-reported exac-
erbations and future exacerbations. Furthermore, com-
bining C4Ma3 and fibrinogen improved the prediction
of mortality, but the combination was not related to fu-
ture exacerbations. These results indicate that C4Ma3
may be able to identify COPD subjects with high disease
activity and poor prognosis alone or in combination with
the current FDA approved biomarker plasma fibrinogen.
Additional file
Additional file 1: Table S1. Ethics and review boards. (PDF 169 kb)
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